These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 30240478)

  • 21. What Is the Value of Counting Mast Cells in Gastrointestinal Mucosal Biopsies?
    Panarelli NC; Hornick JL; Yantiss RK
    Mod Pathol; 2023 Feb; 36(2):100005. PubMed ID: 36853780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mast cells and mastocytosis.
    Söderholm JD
    Dig Dis; 2009; 27 Suppl 1():129-36. PubMed ID: 20203509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful treatment of mast cell activation syndrome with sunitinib.
    Afrin LB; Cichocki FM; Patel K; Molderings GJ
    Eur J Haematol; 2015 Dec; 95(6):595-7. PubMed ID: 26072665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.
    Pardanani A
    Am J Hematol; 2013 Jul; 88(7):612-24. PubMed ID: 23720340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nerve growth factor content is increased in the rectal mucosa of children with diarrhea-predominant irritable bowel syndrome.
    Willot S; Gauthier C; Patey N; Faure C
    Neurogastroenterol Motil; 2012 Aug; 24(8):734-9, e347. PubMed ID: 22625872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management.
    Pardanani A
    Am J Hematol; 2015 Mar; 90(3):250-62. PubMed ID: 25688753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Curcumin Ingestion Inhibits Mastocytosis and Suppresses Intestinal Anaphylaxis in a Murine Model of Food Allergy.
    Kinney SR; Carlson L; Ser-Dolansky J; Thompson C; Shah S; Gambrah A; Xing W; Schneider SS; Mathias CB
    PLoS One; 2015; 10(7):e0132467. PubMed ID: 26147007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological treatment options for mast cell activation disease.
    Molderings GJ; Haenisch B; Brettner S; Homann J; Menzen M; Dumoulin FL; Panse J; Butterfield J; Afrin LB
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Jul; 389(7):671-94. PubMed ID: 27132234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mastocytosis - an update.
    Amon U; Hartmann K; Horny HP; Nowak A
    J Dtsch Dermatol Ges; 2010 Sep; 8(9):695-711; quiz 712. PubMed ID: 20678151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A case of neuropathic pain in monoclonal mast cell activation syndrome.
    Bay JL; Sedarsky KE; Petersen MM
    Ann Allergy Asthma Immunol; 2018 May; 120(5):543-544. PubMed ID: 29481890
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunopharmacological modulation of mast cells.
    Borriello F; Granata F; Varricchi G; Genovese A; Triggiani M; Marone G
    Curr Opin Pharmacol; 2014 Aug; 17():45-57. PubMed ID: 25063971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mast Cells as Drivers of Disease and Therapeutic Targets.
    Siebenhaar F; Redegeld FA; Bischoff SC; Gibbs BF; Maurer M
    Trends Immunol; 2018 Feb; 39(2):151-162. PubMed ID: 29196147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mast Cell Disorders In Drug Hypersensitivity.
    Bonadonna P; Bonifacio M; Zanotti R
    Curr Pharm Des; 2016; 22(45):6862-6869. PubMed ID: 27779084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gastrointestinal Involvement in Mast Cell Activation Disorders.
    Hsieh FH
    Immunol Allergy Clin North Am; 2018 Aug; 38(3):429-441. PubMed ID: 30007461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11β-prostaglandin2α.
    Ravi A; Butterfield J; Weiler CR
    J Allergy Clin Immunol Pract; 2014; 2(6):775-8. PubMed ID: 25439370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms.
    Valent P; Sperr WR; Schwartz LB; Horny HP
    J Allergy Clin Immunol; 2004 Jul; 114(1):3-11; quiz 12. PubMed ID: 15241337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mastocytosis: review of clinical and experimental aspects.
    Hartmann K; Bruns SB; Henz BM
    J Investig Dermatol Symp Proc; 2001 Nov; 6(2):143-7. PubMed ID: 11764303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional gastrointestinal disorders and mast cells: implications for therapy.
    Barbara G; Stanghellini V; De Giorgio R; Corinaldesi R
    Neurogastroenterol Motil; 2006 Jan; 18(1):6-17. PubMed ID: 16371078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mastocytosis.
    Golkar L; Bernhard JD
    Lancet; 1997 May; 349(9062):1379-85. PubMed ID: 9149712
    [No Abstract]   [Full Text] [Related]  

  • 40. Current treatment options in patients with mastocytosis: status in 2015 and future perspectives.
    Arock M; Akin C; Hermine O; Valent P
    Eur J Haematol; 2015 Jun; 94(6):474-90. PubMed ID: 25753531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.